OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL

July 12th 2017

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.

Dr. Parikh on the Applicability of Liquid Biopsies in Gastrointestinal Cancers

July 12th 2017

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses the applicability of liquid biopsies in gastrointestinal cancers.

Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer

July 11th 2017

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

Dr. Loeb on Determining Beneficial Test Options for Prostate Cancer

July 11th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses how to determine which test will be beneficial for the management of prostate cancer.

Dr. Agarwal on Potential Agents for Metastatic Hormone-Sensitive Prostate Cancer

July 11th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses potential agents for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Siegel on Results of Chemotherapy and Transoral Surgery Study for Head and Neck Cancer

July 11th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses a phase II study investigating induction chemotherapy and transoral surgery for patients with head and neck cancer.

Dr. Shah on CAR T-cell Therapy's Effectiveness in ALL

July 11th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

Dr. Garcia on Sequencing Immunotherapies in Bladder Cancer

July 11th 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the optimal sequence of immunotherapies for the treatment of patients with bladder cancer.

Dr. Pinato Discusses Pheochromocytomas and Paragangliomas

July 10th 2017

David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses pheochromocytomas and paragangliomas.

Dr. O'Neil on Next Steps for Napabucasin With FOLFIRI and Bevacizumab in CRC

July 10th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer.

Dr. Bruix Discusses Progress of Second-Line Treatment in HCC

July 10th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma.

Dr. Levine on the PARP Inhibitor Landscape for Ovarian Cancer

July 7th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the PARP inhibitor landscape for patients with ovarian cancer.

Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma

July 7th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.

Dr. Chi on Combinations with Androgen Deprivation Therapy for Prostate Cancer

July 7th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses combinations with androgen deprivation therapy for patients with prostate cancer.

Dr. Yardley on the Results of the APT and APHINITY Trials for HER2+ Breast Cancer

July 7th 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the results of the APT and APHINITY trials for patients with HER2-positive breast cancer.

Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer

July 7th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.

Dr. Siegel on the Treatment of HPV-Associated Head and Neck Cancer

July 7th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the treatment for patients with HPV-associated head and neck cancer.

Dr. Huffman on Survival Analysis of Patients With Pseudopapillary Tumors of the Pancreas

July 7th 2017

Brandon Huffman, MD, resident physician, internal medicine, Mayo Clinic, discusses the survival analysis from a study of patients with solid pseudopapillary tumors of the pancreas.

Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer

July 7th 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.

Dr. Apolo on the Combination of Cabozantinib Plus Nivolumab in Urothelial Carcinoma

July 7th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with urothelial carcinoma.